MCBÜ Açıkerişim Sistemi :: Browsing by Author "Aydemir O."

Browsing by Author "Aydemir O."

Now showing 1 - 20 of 46

Depression and anxiety in hyperthyroidism
(2002) Demet M.M.; Özmen B.; Deveci A.; Boyvada S.; Adigüzel H.; Aydemir O.
Background. Our objective was to determine symptomatology of depression and anxiety in patients with untreated hyperthyroidism and compare with euthyroid patients. Methods. Thirty-two patients with hyperthyroidism (high free T3 and free T4, and suppressed TSH) and 30 euthyroid (normal free T3, free T4, and TSH) controls attending the Endocrinology Out-Patient Department at Celal Bayar University Hospital in Manisa, Turkey were included in the study. Hormonal screening was performed by immunoassay and hemagglutination method. For psychiatric assessment, Hospital Anxiety and Depression Scale [HAD], Hamilton Depression Rating Scale [HAM-D], and Hamilton Anxiety Rating Scale [HAM-A] were used. There was no difference between the two groups in terms of demographic features. Results. Total scores obtained both from HAM-D and HAM-A were significantly greater in the hyperthyroidism group than that of the euthyroid group (p <0.05); there was no difference in terms of HAD. When compared in terms of symptomatology, early insomnia (HAM-D#6), work and activities (HAM-D#7), psychic anxiety (HAM-D#10), weight loss (HAM-D#16), insomnia (HAM-A#4), and cardiovascular symptoms (HAM-A#8) were significantly more frequent in the hyperthyroidism group. By Wilks lambda discriminant analysis, psychomotor agitation (HAM-D#9), weight loss (HAM-D#16), and insomnia (HAM-A#4) were found as the discriminating symptoms for the hyperthyroidism group, whereas somatic anxiety (HAM-A#11) and loss of interest (HAD#14) were distinguishing symptoms of the euthyroidism group. Conclusions. Hyperthyroidism and syndromal depression-anxiety have overlapping features that can cause misdiagnosis during acute phase. For differential diagnosis, one should follow-up patients with hyperthyroidism with specific hormonal treatment and evaluate persisting symptoms thereafter. In addition to specific symptoms of hyperthyroidism, psychomotor retardation, guilt, muscle pain, energy loss, and fatigue seem to appear more frequently in patients with comorbid depression and hyperthyroidism; thus, presence of these symptoms should be a warning sign to nonpsychiatric professionals for the need for psychiatric consultation. © 2002 IMSS. Published by Elsevier Science Inc.
Depression and anxiety in hypothyroidism
(2003) Demet M.M.; Ozmen B.; Deveci A.; Boyvada S.; Adiguzel H.; Aydemir O.
The aim of the study was to determine the prevalence and severity of depression and anxiety inpatients with hypothyroidism and to compare this with euthyroid patients. Thirty patients with hypothyroidism and 30 euthyroid controls attending the Endocrinology outpatient department of Celal Bayar University, Medical Faculty were included in the study. The hormonal screening was done by immunoassay and haemagglutination methods. Then, for psychiatric assessment, Hospital Anxiety and Depression Scale (HAD), Hamilton Depression Rating Scale (HAM-D), and Hamilton Anxiety Rating Scale (HAM-A) were used. There was no difference between the two groups in terms of demographic features. Total scores obtained from the scales used in the study did not differ significantly (p > 0.05). The frequency of items of both HAM-D and HAM-A did not show any differences in the two groups. By Wilks' Lambda discriminant analysis, depressive mood (HAM-D#1) was found to be the discriminating feature between the hypothyroid group and the euthyroid group. Therefore, depression and anxiety were not outstanding features in hypothyroidism. However, depression was more significant in the hypothyroid than euthyroid group.
Public attitudes to schizophrenia in rural Turkey
(2003) Taskin E.O.; Seyfe Sen F.; Aydemir O.; Demet M.M.; Ozmen E.; Icelli I.
Background. The aim of this study was to determine the public's attitudes and their correlates towards patients with schizophrenia in rural areas. Methods. The study was carried out in a village near Manisa City, Turkey. Two hundred and eight subjects completed the public survey form which consists of ten items screening demographic and health status and 32 items rating attitudes towards schizophrenia. Results. Half of the subjects stated that persons with schizophrenia are aggressive and that they should not be free in the community. More than half of the subjects stated that they would be irritated about having a neighbour with schizophrenia (61.5%), that they would not rent their home to a person with schizophrenia (58.2%), that they do not want to work with a person with schizophrenia (61.1%), and that they would not get married to a person with schizophrenia (85.6%). Conclusions. The public in rural areas sufficiently recognises schizophrenia but has a tendency to stigmatise schizophrenic patients. Their attitudes are generally negative and rejective. They do not want close contact with schizophrenic patients. Interpretation of schizophrenia as a mental illness leads to more negative attitudes and increases the social distance.
The impact of co-morbid conditions on the SF-36: A primary-care-based study among hypertensives
(Elsevier Inc., 2005) Aydemir O.; Ozdemir C.; Koroglu E.
Background. Comorbidities in hypertension complicate the course causing more symptoms and deterioration in a patient's daily life. The aim of this present study is to describe the effect of comorbid conditions on health-related quality of life (HRQL) in hypertensive patients. Methods. The study was carried out in four different regions of Turkey by 156 general practitioners between October 1999 and April 2000. In addition to cardiological evaluation, SF-36 health survey questionnaire was used for quality of life measurement. Diagnosis of comorbid conditions were anamnesis based. Results. The mean age of the group (n = 938) was 58.1 ± 11.2, and 58.6% (n = 550) of the group was female. Total scores of the eight domains of SF-36 were lower than the normal population scores. Age and gender affected every domain of SF-36 scale negatively. Heart failure affected four of the domains, primarily physical domains. Previous transient ischemic attack was responsible for low HRQL in emotional role difficulties, vitality, and mental health, but previous stroke had an impact on physical functioning and emotional role. Previous myocardial infarction affected emotional role difficulties negatively whereas previous CABG surgery had a positive impact on the same domain. Obesity and angina pectoris affected physical functioning negatively, whereas peripheral arterial disease caused low general health perception. Nephropathy, retinopathy and diabetes had no impact on HRQL in hypertension. Conclusions. When the contribution of comorbid conditions is taken into consideration, it can be noticed that the impact of every other condition is similar to the same condition when it is pure. Hypertension per se seems to cause less impairment than expected in HRQL. © 2005 IMSS. Published by Elsevier Inc.
Sexual dysfunction in patients with allergic rhinoconjunctivitis
(American College of Allergy, Asthma and Immunology, 2005) Kirmaz C.; Aydemir O.; Bayrak P.; Yuksel H.; Ozenturk O.; Degirmenci S.
Background: Sexual dysfunction in chronic diseases has recently attracted attention owing to its impact on quality of life (QoL). Allergic rhinoconjunctivitis (ARC) affects QoL, causing limitations in many areas. However, there has not been research on changes in sexual function in patients with ARC. Objective: To report the effect of ARC and its treatment on sexual function in men and women. Methods: Forty-three sexually active patients with seasonal ARC aged 22 to 49 years were included in the study. The control group was composed of 40 healthy individuals aged 22 to 46 years. Conjunctival symptom scores (CSSs) and nasal symptom scores (NSSs) of patients with symptomatic ARC were determined, as were sexual function scores (SFSs) using the Female Sexual Function Index and the International Index of Erectile Function during allergen exposure in the pollination period and after treatment with oral desloratadine, 5 mg/d, for 30 days. The SFSs were evaluated in the control group. Results: The CSSs and NSSs significantly improved in treated ARC (P < .001). In women, Female Sexual Function Index results in symptomatic ARC were significantly lower than in treated ARC and controls (P = .003). In men, International Index of Erectile Function results in treated ARC (P = .001) and controls (P < .001) were significantly higher than in symptomatic ARC. Furthermore, correlation between improvement in CSSs and NSSs and that of SFSs was determined (P = .007 for women; P = .001 for men). Conclusion: Improvement in sexual function as a variable of QoL may accompany the treatment of symptoms in patients with ARC.
Antisocial Personality Disorder: A Review
(John Wiley & Sons, Ltd, 2005) Cloninger C.R.; Gacono C.B.; Hill J.; Oldham J.M.; Robins L.N.; Stevenson J.L.; Black D.W.; Duggan C.; Widiger T.A.; Alarcón R.D.; Girolamo G.D.; Bassi M.; Küey L.; Aydemir O.
[No abstract available]
The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: A preliminary study
(Elsevier Inc., 2005) Aydemir O.; Deveci A.; Taneli F.
Recent studies suggested a role of brain-derived neurotrophic factor (BDNF) in depression. While BDNF levels are lower in depressed patients, antidepressant treatment increases serum BDNF levels of depressed patients. Our study aims to test the effect of chronic venlafaxine treatment on serum BDNF levels in patients with a major depressive disorder. Ten patients diagnosed as major depressive disorder according to DSM-IV are included in the study. Two of the patients had their first episode and were drug-naive, the other eight patients were drug-free for at least 4 weeks. The severity of depression was assessed with Hamilton Depression Rating Scale (HDRS). The control group consisted of ten age- and sex-matched subjects without any psychiatric disorder. Blood samples were collected at the baseline and after 12 weeks of antidepressant treatment (during remission). At the baseline the mean serum BDNF level was 17.9±9.1 ng/ml and the mean HDRS score was 23.2±4.6. Serum BDNF levels of the study group were significantly lower than in the control group (31.6±8.6 ng/ml). At the end of the study, the mean serum BDNF level was 34.6±7.1 ng/ml whereas the mean HDRS score was 8.2±3.9. From the baseline to the remission after 12 weeks of treatment, the increase in serum BDNF level and the decrease in HDRS score were statistically significant, respectively. When we compared the serum BDNF level of depressed patients at remission to that of the controls, there was no statistically significant difference. This study shows that venlafaxine treatment of depression improves serum BDNF level which may be considered as a nonspecific peripheral marker of depression. © 2004 Elsevier Inc. All rights reserved.
Aretaeus of Cappadocia
(Blackwell Publishing Ltd, 2007) Aydemir O.; Malhi G.S.
[No abstract available]
Serum brain-derived neurotrophic factor levels in conversion disorder: Comparative study with depression
(2007) Deveci A.; Aydemir O.; Taskin O.; Taneli F.; Esen-Danaci A.
The aim of the present study was to compare serum brain-derived neurotrophic factor (BDNF) levels of patients with major depressive disorder (MDD) and conversion disorder (CD). Serum BDNF levels were measured in the following three groups: 15 CD patients without any comorbid diagnosis of psychiatric disorder, 24 patients with MDD, and 26 healthy subjects without any psychiatric diagnosis or psychiatric treatment. The serum BDNF level of the healthy control group (31.4 ± 8.8 ng/mL) was statistically higher than the level of the MDD group (21.2 ± 11.3 ng/mL) and the CD group (24.3 ± 9.0 ng/mL; P = 0.008). This suggests that BDNF level may play a similar role in the pathophysiology of MDD and CD. © 2007 The Authors.
Serum BDNF levels in suicide attempters related to psychosocial stressors: A comparative study with depression
(2008) Deveci A.; Aydemir O.; Taskin O.; Taneli F.; Esen-Danaci A.
Although many studies have examined the neurobiological aspects of suicide, the molecular mechanisms and pathophysiologic mechanisms associated with suicide remain unclear. In this study, it is aimed to investigate whether there is a difference in serum brain-derived neurotrophic factor (BDNF) levels among suicide attempters without a major psychiatric disorder, compared to major depressive disorder patients and healthy subjects. It was undertaken with the hypothesis that suicide per se lowers serum BDNF levels, since it is a source of stress. The study was carried out in Celal Bayar University Hospital, Manisa, Turkey. Ten suicide attempters, 24 patients with major depressive disorder and 26 subjects without any psychiatric diagnosis and any psychiatric treatment were included in the study. All subjects were asked to give their written consent. Blood samples were collected at the baseline. Serum BDNF was kept at -70°C before testing, and assayed with an ELISA kit (Promega; Madison, Wisc., USA) after dilution with the block and sample solution provided with the kit. The data were subjected to the Kruskal-Wallis test for nonparametric analysis of variance. Mean serum BDNF levels were significantly lower in the suicide group (21.2 ± 12.4 ng/ml) and the major depressive disorder group (21.2 ± 11.3 ng/ml) than the control group (31.4 ± 8.8 ng/ml; p = 0.004). These results suggest that BDNF may play an important role in the neurobiology of suicidal behavior. BDNF levels may be a biological marker for suicidal behavior. To investigate the role of BDNF in suicide, further studies with a wider sample size and a variety of psychiatric diagnoses accompanying suicide attempt are needed. Copyright © 2007 S. Karger AG.
The effects of residual affective symptoms on cognitive and social functioning in remitted bipolar patients; [Remisyondaki iki uçlu hastalarda kalinti duygudurum belirtilerinin bilişsel ve toplumsal işlevsellik üzerine etkisi]
(2009) Kaya E.; Aydemir O.; Selçuki D.
Objective: In bipolar disorder, both cognitive and social functioning is impaired during remission. It is not well documented whether residual affective symptoms cause impairment in cognitive and social functions or cognitive impairment per se is the source of psychosocial dysfunction during remission. In this work, the effects of subsyndromal residual affective symptoms on cognitive and social functioning in remitted bipolar patients are studied. Materials and Methods: The study was carried out with 43 patients diagnosed as bipolar I disorder with a remission for at least 6 months. The mean age of the patients was 38.1±13.5 and 55.8% (n=24) were male. The mean duration of illness was 12.1±10.2 years and the mean number of previous episodes was 6.6±6.0. As healthy controls, 22 volunteers without any lifetime psychiatric and medical diagnosis or treatment were invited to the study. In the assessment Hamilton Depression Rating Scale (HAM-D), Young Mania Rating Scale (YMRS), Stroop Test, Auditory Verbal Learning Test (AVLT), increased latency positive-evoked potentials (P300), Global Assessment of Functioning Scale (GAF), and Social Functioning Scale (SFS) were used. In statistical analyses, linear regression analysis was performed. Results: HAM-D scores significantly affected cognitive functions such as P300 amplitude, immediate recall, verbal learning, delayed recall, recognition, retrieval, Stroop effect, and social functions such as social engagement, interpersonal behavior, prosocial activities, recreation, independence-performance and competency and employment. YMRS scores affected only verbal learning. Cognitive functions do not have any effect on mood symptoms or social functions. Discussion and Conclusion: Subsyndromal residual depressive symptoms seem to affect functioning in remitted bipolar patients. In order to improve the functioning of the bipolar patients, it will be helpful to implement strategies for these depressive symptoms.
Beliefs and attitudes of physicians dealing with cancer patients about quality of life: A comparative study; [Kanser hastalanyla çalişan hekimlerin yaşam kalitesine yönelik inang ve tutumlari: Karsy̧ilaştirmali bir çalişma]
(2009) Aydemir O.; Çelik P.; Müezzinoǧlu T.
Objective: This study was designed to determine the beliefs and attitudes of physicians dealing with cancer patients about quality of life. Materials and methods: For determining the beliefs and attitudes of physicians about quality of life, a 32-item questionnaire was developed, inspired by the questionnaire developed by Bezjak et al. Two diverse specialties of physicians were enrolled, including 44 urologists, and 73 chest physicians. Results: It was found that all physicians had positive beliefs about quality of life, but they mainly relied on their own clinical experience instead of scales. When the two groups were compared, chest physicians seemed to accord more importance to prolong the patients' survival and to biological parameters in choosing the treatment than did urologists. Conclusion: All physicians dealing with cancer care have positive attitudes towards quality of life assessments. Chest physicians weight quality of life as a lowrank issue compared to urologists in the care of cancer patients. This seems to be due to high mortality rates of lung cancer.
Mirtazapine combination in treatment-resistant major depressive disorder: A retrospective evaluation of six weeks
(2009) Aydemir O.; Deveci A.; Taskin E.O.
Objective: Despite the adequate time and dose of antidepressant treatment, approximately one-third of the patients with major depression do not respond. In previous trials, mirtazapine combination was found to be efficacious in treatment-resistant depression which is non-response to two previous adequate antidepressant drug treatments from different classes. In this present study, it is aimed to assess the efficacy and the tolerability of mirtazapine combination treatment in patients with treatment-resistant major depression by retrospective chart review. Method: During the period between August 2004 and July 2005, all the charts of the patients with treatment resistant major depressive disorder were selected. For the assessment, Hamilton Depression Rating Scale (HAM-D) and Clinical Global Impression (CGI) were used. For the assessment of adverse effects, the report of the patients was considered. Forty-three in- or outpatients with major depression who previously received two antidepressants of different groups and did not respond (<50% of symptom reduction in HAM-D) to either treatment were assessed. Of the 43 patients who fulfilled the inclusion criteria, 39 patients had complete data for the assessment. The study was based on the chart records of 39 patients. At the time of assessment, 18 (41.9%) patients were receiving venlafaxine, and 25 (58.1%) patients were receiving an SSRI (15 on citalopram, 6 on sertraline, and 4 on paroxetine). Result: The mean age of the study group was 42.2±12.9, and 74.4% (n=32) female. Of the whole sample, 14 (32.6%) patients were having their first episode, whereas 29 (67.4%) patients had a recurrent major depression. Ten (23.3%) patients were inpatients and 33 (76.7%) patients were outpatients. The mean HDRS score was decreased from 23.1±5.1 to 73±5.6 at the end of the assessment of six weeks, and 21 (53.8%) patients achieved remission (HDRS<7). When the primary antidepressant was taken into consideration, patients on venlafaxine had significantly more remission rate compared to patients on selective serotonin reuptake inhibitors (SSRI). In 27.9% (n=12) of the patients, adverse events were emerged, and weight gain was predominant with 8 patients. In two patients who were dropped out due to adverse events, one patient experienced weight gain (8 kg/4 weeks) and the other had anxiety and agitation. Discussion: Mirtazapine combination treatment is an efficacious and well-tolerated alternative in treatment-resistant major depression. When the primary antidepressant is venlafaxine, this combination therapy seems to be more effective.
New delirium rating scale for ICU; [yoǧun bakım olgularinda yeni deliryum deǧerlendirme skalası]
(Turkish Neuropsychiatric Society, 2010) Ok G.; Aydemir O.; Tok D.; Erbüyün K.; Turan E.
Objective: The New Delirium Rating Scale (NDRS) makes use of verbal assessments to evaluate the cardinal features of delirium and is an observer-rated, 10-item symptom rating scale based on both DSM-IV and the findings of the previous clinical research. In this study, we tested the validity of the NDRS for measuring the severity of delirium in intensive care units. Methods: Thirty consecutive non-intubated patients admitted to the ICU for more than 24 hours were included in the study. Two intensivists were trained to rate delirium according to NDRS and they daily carried out structured interviews to evaluate the patients. All patients were interviewed by a psychiatrist for rating according to NDRS, and the data collected by the psychiatrist and the intensivists were compared. Results: The cut-off score for NDRS was 11.3 patients (10%), who were rated as delirious. The inter-rater reliability of the intensivists and the psychiatrist was found to be 0.84 and 0.90, respectively (p<0.0001). Conclusion: Intensivists easily used NDRS, a detailed delirium assessing scale, and rated delirium successfully. © Archives of Neuropsychiatry, published by Galenos Publishing.
The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC)
(2010) Yatham L.N.; Torres I.J.; Malhi G.S.; Frangou S.; Glahn D.C.; Bearden C.E.; Burdick K.E.; Martínez-Arán A.; Dittmann S.; Goldberg J.F.; Ozerdem A.; Aydemir O.; Chengappa K.N.R.
Objectives: Although cognitive impairment is recognized as an important clinical feature of bipolar disorder, there is no standard cognitive battery that has been developed for use in bipolar disorder research. The aims of this paper were to identify the cognitive measures from the literature that show the greatest magnitude of impairment in bipolar disorder, to use this information to determine whether the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB), developed for use in schizophrenia, might be suitable for bipolar disorder research, and to propose a preliminary battery of cognitive tests for use in bipolar disorder research. Methods: The project was conducted under the auspices of the International Society for Bipolar Disorders and involved a committee that comprised researchers with international expertise in the cognitive aspects of bipolar disorder. In order to identify cognitive tasks that show the largest magnitude of impairment in bipolar disorder, we reviewed the literature on studies assessing cognitive functioning (including social cognition) in bipolar disorder. We further provided a brief review of the cognitive overlap between schizophrenia and bipolar disorder and evaluated the degree to which tasks included in the MCCB (or other identified tasks) might be suitable for use in bipolar disorder. Results: Based on evidence that cognitive deficits in bipolar disorder are similar in pattern but less severe than in schizophrenia, it was judged that most subtests comprising the MCCB appear appropriate for use in bipolar disorder. In addition to MCCB tests, other specific measures of more complex verbal learning (e.g., the California Verbal Learning Test) or executive function (Stroop Test, Trail Making Test-part B, Wisconsin Card Sorting Test) also show substantial impairment in bipolar disorder. Conclusions: Our analysis reveals that the MCCB represents a good starting point for assessing cognitive deficits in research studies of bipolar disorder, but that other tasks including more complex verbal learning measures and tests of executive function should also be considered in assessing cognitive compromise in bipolar disorder. Several promising cognitive tasks that require further study in bipolar disorder are also presented. © 2010 The Authors. Journal compilation © 2010 John Wiley & Sons A/S.
Therapeutic goals, clinical indicators and follow up in major depressive disorder; [Major depresif bozuklukta tedavi hedefleri ve tedavinin izlenmesi]
(Cukurova Univ Tip Fakultesi Psikiyatri Anabilim Dali, 2011) Aydemir O.
Major depressive disorder constitutes a very important health problem because of its associated disability. The treatment plan for depression should included targets, since the better the goals are described, the more likely the treatment will be followed up and monitored. For this purpose, clinical psychiatric scales are useful. Psychiatric rating scales are instruments to monitor depression and its treatment in a useful and operational way. Response may be the most important criterion to be monitored and is defined as a 50% reduction in the index scale score. Inadequate response to the treatment is defined as a 25-50% reduction and no response to treatment is defined as a reduction below 25%. Remission is defined as the improvement of most symptoms and during the monitoring of remission the target response is a score below the cutoff score, e.g. reduction of the Hamilton Depression Rating Scale below 7 and reduction of the Montgomery Asberg Scale below 10. While these two scales are the most used instruments in monitoring the treatment of depression, self-rated scales, while less preferred, may also be used. In the global assessment of patients, the Clinical Global Impression scale may be used. The achievement of remission in depression lowers healthcare costs significantly, reduces disease burden, improves quality of life, and reduces medical and psychiatric morbidity and mortality. Even though the functionality of patients improves,when assessed subjectively, it is not possible to suggest that it reaches premorbid levels; thus, in the follow-up of patients, functionality should be monitored, as well as response and remission.
Association of social anxiety with stigmatisation and low self-esteem in remitted bipolar patients
(Cambridge University Press, 2011) Aydemir O.; Akkaya C.
Background: In remitted bipolar disorder, it is aimed to show the association between social anxiety, self-esteem and stigmatisation. Methods: From two university clinics, a sample of 150 remitted bipolar patients was included in this study. Patients were assessed with Liebowitz Social Anxiety Scale, Rosenberg Self-Esteem Scale and sense of stigmatisation subscale of Bipolar Disorder Functioning Questionnaire (Stigma) and were rated with Hamilton Depression Rating Scale and Young Mania Rating Scale for mood symptoms. Confirmatory path analysis was performed. Results: The mean age of the patients was 39.5, and 52.7% (n = 79) were female. Ninety per cent (n = 135) of the patients had bipolar I disorder. The mean duration of the illness was 13.4 years and the mean number of episodes was 7.8. The model was subjected to confirmatory path analysis and the goodness-of-fit index was calculated to be 0.909, the confirmatory fit index was found to be 0.902 and the root mean square error of approximation was 0.097. Self-esteem was negatively associated with stigmatisation (r = -0.746). Social anxiety was positively associated with self-esteem (r = 0.494). Social anxiety was negatively associated with stigmatisation (r = -0.381). Conclusions: In remitted bipolar patients, social anxiety is very high and this social anxiety seems to be caused by self-stigmatisation and low self-esteem. © 2011 John Wiley & Sons A/S.
Quality of life, anxiety, depression and knowledge of disease in patients with behçet's diseases; [Behçetli̇ hastalarda yaşam kali̇tesi̇, anksi̇yete, depresyon ve hastalik hakkindaki̇ bi̇lgi̇ler]
(2011) Havlucu D.Y.; Inanir I.; Aydemir O.
Behçet's disease (BD) is a chronic inflammatory disease which affects several organs and systems. Chronic course with frequent relapses, painful involvements, mortality and morbidity risk cause impairment in patients' quality of life. Thirty three patients with BD and 33 sex and age matched controls were given Short Form-36 (SF-36), Hospital Anxiety and Depression Scale, and a questionnaire about knowledge. on the disease. In BD group, anxiety and depression were more frequent, and SF-36 scores were lower except physical function and vitality when compared to controls. HAD and SF-36 scores were independent from disease activity and sex. In patients with systemic involvement, lower mental health, physical and emotional role scores and increased HAD-anxiety and HAD-depression scores were determined. Patients pointed out health physicians (81%), media (64%) and other patients (33%3) as information sources. They had also higher knowledge levels in comparison to controls. Psychological health and quality of life are impaired in patients with BD. Therefore a psychiatric evaluation and approach will be useful in addition to the medical management.
Evolution of a histrorical system to a new temperament model: Nine types temperament model; [Tarihsel bir sistemin yeni bir mizaç modeline evrimi: Dokuz tip mizaç modeli]
(2011) Yilmaz E.D.; Gençer A.G.; Aydemir O.
[No abstract available]
Parental attitude in women with hyperprolactinemia: A controlled cross-sectional study; [Ailesel tutumun hiperprolaktinemi üzerine etkisi: Kesitsel kontrollü bir çalışma]
(Turkish Biochemistry Society, 2011) Ulman C.; Aydemir O.; Taneli F.; Aksun S.; Öztin A.; Cennet S.; Laçin S.
Objective: Prolactin hormone affects the brain, attitude and mood. Secretion of prolactin may be stimulated by environmental factors. The aim of this study was to demonstrate any possible effect of poor child-parent relationship on hyperprolactinemia. We hypothesize that women with hyperprolactinemia may have been subjected to poor child-parent relationship and neglect. Method: The present study was designed in a maternity hospital and included women with gynecologic complaints referred from the gynaecology outpatient clinic for serum prolactin assessments. An 85-item, self-rated EMBU Scale questionnaire (a scale for perceived parental attitude) was applied. Fifty women were enrolled over a period of 5 months. Results: Women with hyperprolactinemia (prolactin levels above 26 ng/ml) constituted the patient group (Group 1) (n=34) and those with normal serum prolactin levels (below 26 ng/ ml) served as the controls (Group 2) (n=16). The mean±SD levels of prolactin for group 1 and 2 were 57.25±38.7 ng/ml and 18.81±4.4 ng/ml, respectively. Group 1 patients believe that their parents did not show enough emotional warmth and had rejective behavior. Emotional warmth parameters of patients' mothers and fathers were significantly lower (p=0.002 and p=0.01, respectively) than those of the control group. We also found that the patients believed that their mothers and fathers both had rejective behaviors (p=0.008 and p= 0.009, respectively). Conclusion: Prolactin secretion is regulated by the dopaminergic system and since dopamine is responsible of pleasure and satisfaction sensations, the negative affection of both mothers and fathers in childhood may play a role in the etiology of chronic low-grade hyperprolactinemia in women. © TurkJBiochem.com.

Browsing by Author "Aydemir O."

Results Per Page

Sort Options